8-K Announcements
6Material company update
Aug 6, 2026·SEC
Material company update
Feb 13, 2026·SEC
Material company update
Feb 13, 2026·SEC
ProPhase Labs faces a critical inflection point as it struggles to transition from its post-pandemic diagnostic revenue base, evidenced by a persistent revenue decline and recurring net losses. The company's financial stability is severely compromised by a pre...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 19, 2026 | -$0.22 vs — | $1M vs — |
Q3 2026 Jun 30, 2026 | -$0.43 vs — | $478,000 vs — |
Q3 2026 Jun 24, 2026 | -$0.87+27.5% vs -$1.20 | $784,000-91.9% vs $10M |
Q3 2026 Jun 22, 2026 | -$0.87+27.5% vs -$1.20 | $784,000-91.9% vs $10M |
Benchmark PRPH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ProPhase Labs, Inc. (PRPH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.01 | $126.15K | -0.01 | -35.82% | -339.31% | -271.49% | — | |
| $10.34 | $705.09M | -0.62 | -1.89% | -39.2% | -55.3% | — | |
| $4.57 | $2.37B | -26.88 | 40.34% | -0.74% | -5.38% | — | |
| $1.70 | $19.51M | -0.35 | -7.37% | -106.58% | -78.78% | — | |
| $390.79 | $55.97B | -257.10 | 35.9% | -7.11% | -11.73% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — |
ProPhase Labs, Inc. (PRPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ProPhase Labs, Inc. (PRPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Feb 13, 2026·SEC
Feb 13, 2026·SEC
Get notified when PRPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ProPhase Labs, Inc. (PRPH) stock FAQ — growth, dividends, profitability & financials explained
ProPhase Labs, Inc. (PRPH) reported $3.2M in revenue for fiscal year 2025. This represents a 295% increase from $0.8M in 1996.
ProPhase Labs, Inc. (PRPH) saw revenue decline by 35.8% over the past year.
ProPhase Labs, Inc. (PRPH) reported a net loss of $22.6M for fiscal year 2025.
ProPhase Labs, Inc. (PRPH) has a return on equity (ROE) of -271.5%. Negative ROE indicates the company is unprofitable.
ProPhase Labs, Inc. (PRPH) had negative free cash flow of $30.7M in fiscal year 2025, likely due to heavy capital investments.